Truist Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)

August 5, 2025 7:37 AM EDT Send to a Friend
Truist Securities analyst Joon Lee reiterated a Buy rating and $85.00 price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX).The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login